ArticleGenetics in medicine : official journal of the American College of Medical Genetics2014
The business of genomic testing: a survey of early adopters.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review.Future oncology (London, England) · 2024Pooled it
- Patient and Provider Experiences With Precision Oncology: Qualitative Descriptive Study at the Department of Veterans Affairs.JMIR cancer · 2026Article
- Landscape of cancer biomarker testing in England following genomic services reconfiguration: insights from a nationwide pathologist survey.Journal of clinical pathology · 2024Article
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.Genetics in medicine : official journal of the American College of Medical Genetics · 2020Article
- Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.European journal of human genetics : EJHG · 2018Article
- The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies.Journal of visualized experiments : JoVE · 2016Article
- Utility before business.Genetics in medicine : official journal of the American College of Medical Genetics · 2014Article
- Academic Pathology: A New Journal.Academic pathologyArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe practice of "genomic" (or "personalized") medicine requires the availability of appropriate diagnostic testing. Our study objective was to identify the reasons for health systems to bring next-generation sequencing into their clinical laboratories and to understand the process by which such decisions were made. Such information may be of value to other health systems seeking to provide next-generation sequencing testing to their patient populations.
methodsA standardized open-ended interview was conducted with the laboratory medical directors and/or department of pathology chairs of 13 different academic institutions in 10 different states.
resultsGenomic testing for cancer dominated the institutional decision making, with three primary reasons: more effective delivery of cancer care, the perceived need for institutional leadership in the field of genomics, and the premise that genomics will eventually be cost-effective. Barriers to implementation included implementation cost; the time and effort needed to maintain this newer testing; challenges in interpreting genetic variants; establishing the bioinformatics infrastructure; and curating data from medical, ethical, and legal standpoints. Ultimate success depended on alignment with institutional strengths and priorities and working closely with institutional clinical programs.
conclusionThese early adopters uniformly viewed genomic analysis as an imperative for developing their expertise in the implementation and practice of genomic medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.